Sorting out the multiple roles of Fas ligand

European Journal of Cell Biology

Volumn 79, Issue 8, 2000, Pages 539-543

  Bossi, Giovanna ^a   Stinchcombe, Jane C ^a   Page, Lesley J ^b   Griffiths, Gillian M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cytotoxic T lymphocyte; Fas ligand (CD95 ligand); Secretory lysosome; Sorting

Indexed keywords

CD4 ANTIGEN; FAS LIGAND; METALLOPROTEINASE; PERFORIN;

ARTICLE; CELL GRANULE; CELL KILLING; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYSOSOME; NATURAL KILLER CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; SECRETORY GRANULE; SOLUBILITY; TARGET CELL; TUMOR;

EID: 0033843471     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-9335-00077     Document Type: Article

References (35)

1. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
2. Two signaling pathways can lead to Fas ligand expression in CD8+cytotoxic T lymphocyte clones
3. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells
4. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells
5. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
6. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
7. Lysosomal hydrolases are present in melanosomes and are elevated in melanizing cells
8. Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3-ligand interactions
9. Regulation of the Fas lytic pathway in cloned CTL
10. Fas ligand-induced apoptosis as a mechanism of immune privilege
11. Protein sorting and secretion during CTL killing
12. Secretory lysosomes - A special mechanism of regulated secretion in haemopoietic cells
13. Melanoma cell expression of Fas(Apo-1/ CD95) ligand: Implications for tumor immune escape
14. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
15. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes
16. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
17. Metalloproteinase-mediated release of human Fas ligand
18. FasL - Too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system
19. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
20. Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes
21. Fas and FasL in the homeostatic regulation of immune responses
22. Release of performed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells
23. The Fas death factor
24. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
25. Acid phosphatase activity in secretory granules of pancreatic beta cells of normal rats
26. Fas and Fas ligand interactions suppress melanoma lung metastasis
27. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
28. Chemotactic activity of soluble Fas ligand against phagocytes
29. The tyrosinase tail mediates sorting to the lysosomal compartment in MDCK cells via a di-leucine and a tyrosine-based signal
30. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
31. Expression of the Fas ligand in cells of T cell lineage
32. Turnover of kidney beta-glucuronidase in normal and Chediak-Higashi (beige) mice
33. Downregulation of Fas ligand by shedding
34. Fas ligand in human serum
35. Decreased tumor surveillance in perforin-deficient mice